Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized-dose caspofungin pharmacokinetics in septic shock patients at high risk for invasive candidiasis
ChiCTR1900026998Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of caspofungin in sepsis, septic shock and invasive candidiasis (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Caspofungin plasma concentration and 28-day candidiasis-free survival. Started Sep 2019; status: recruiting.
02
Drugs
caspofungin
03
Conditions
sepsisseptic shockinvasive candidiasis
Beyond the preview
Go deeper on ChiCTR1900026998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026998.